Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MediGene signs up Triton Pharma to commercialise Veregen in Canada

This article was originally published in Scrip

Executive Summary

Triton Pharma, a Canadian company focused on commercialising drugs in women's health, urology and dermatology, has secured an exclusive license and supply agreement from MediGene covering the commercialisation of Veregen ointment to treat genital warts in Canada. Triton takes on responsibility for drug approval i Canada and will pay MediGene up to €2.1 million in milestones plus a double digit royalty on subsequent sales.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts